表紙
市場調查報告書

關注市場分析:神經膠質母細胞瘤

Market Spotlight: Glioblastoma

出版商 Datamonitor Healthcare 商品編碼 914879
出版日期 內容資訊 英文 73 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
關注市場分析:神經膠質母細胞瘤 Market Spotlight: Glioblastoma
出版日期: 2019年12月31日內容資訊: 英文 73 Pages
簡介

Datamonitor Healthcare ,估計2017年的全球神經膠質母細胞瘤的發病案例約有70,000萬案例,至2026年其數量增加到87,100案例。

本報告提供全球神經膠質母細胞瘤市場調查,疾病的背景、概要,患病人數的10年預測,開發平台藥物及已上市藥物概要,臨床試驗狀況,授權、資產收購等的主要交易趨勢,專利資訊,主要藥物的收益預測等資料彙整。

概要

要點

疾病的背景

  • 疾病定義
  • 患者區分
  • 症狀
  • 風險因素
  • 診斷

治療

  • 外科手術
  • 放射線治療
  • 化療
  • 腫瘤治療電場 (TTF)
  • 標靶治療

流行病學

已上市藥物

開發平台藥物

近幾年的活動、分析師的見解

主要的活動

成功的可能性

授權、資產收購等的交易

本源專利

商機

臨床試驗環境

文獻

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0204048

This Market Spotlight report covers the Glioblastoma market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

Datamonitor Healthcare estimates that in 2017, there were approximately 70,000 incident cases of glioblastoma worldwide, and forecasts that number to increase to 87,100 incident cases by 2026. It is estimated that the majority of diagnosed cases were in males in 2017. The incidence of glioblastoma is highest among older individuals aged 75-84 years. Approved drugs in the glioblastoma space focus on DNA, vascular endothelial growth factor, DNA synthesis, protein synthesis, and RNA synthesis. These drugs are administered via the intravenous, intratumoral, and oral routes for GBM.

The majority of industry-sponsored drugs in active clinical development for glioblastoma are in Phase II, with only one drug in the NDA/BLA phase.

Therapies in mid- and late-stage development for glioblastoma focus on a wide variety of targets. The majority of pipeline drugs for glioblastoma are administered via the oral and intravenous routes.

High-impact upcoming events for drugs in the glioblastoma space comprise topline Phase I/II trial results for Calquence, and Phase III updated trial results for DCVax-Brain and Trans Sodium Crocetinate (TSC).

The overall likelihood of approval of a Phase I solid tumors asset is 5.6%, and the average probability a drug advances from Phase III is 40.7%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.3 years in the overall oncology space.

There have been 43 licensing and asset acquisition deals involving glioblastoma drugs during 2014-19. The largest deal during the period was the $548m licensing agreement between I-Mab Biopharma and Genexine in 2017, to develop and commercialize a proprietary long-acting immuno-oncology drug (HyLeukin) in the Greater China territories.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for glioblastoma have been in the early and mid-phases of development, with 92% of trials in Phase I-II, and only 8% in Phase III-IV.

The US has a substantial lead in the number of glioblastoma clinical trials globally. France leads the major EU markets, while Japan has the top spot in Asia.

Clinical trial activity in the glioblastoma space is dominated by completed trials. Merck & Co has the highest number of completed clinical trials for glioblastoma, with 78 trials.

Merck & Co leads industry sponsors with the highest overall number of clinical trials for glioblastoma, followed by Roche.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Disease definition
  • Patient segmentation
  • Symptoms
  • Risk factors
  • Diagnosis

TREATMENT

  • Surgery
  • Radiation therapy
  • Chemotherapy
  • Tumor-treating fields (TTFs)
  • Targeted therapy

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Toca 511 for Glioblastoma (September 12, 2019)
  • Opdivo for Glioblastoma (September 5, 2019)
  • Mvasi for Glioblastoma (June 25, 2019)
  • GammaTile for Glioblastoma (June 17, 2019)
  • Ripretinib for Glioblastoma (June 11, 2019)
  • AG-881 for Glioblastoma (June 3, 2019)
  • Multiple Drugs for Glioblastoma (June 3, 2019)
  • Opdivo for Glioblastoma (May 9, 2019)
  • Optune for Glioblastoma (April 23, 2019)
  • Optune for Glioblastoma (February 28, 2019)
  • Voyager ulRFE System for Glioblastoma (December 14, 2018)
  • SONOCLOUD for Glioblastoma (December 12, 2018)
  • Optune for Glioblastoma (December 1, 2018)
  • MDNA55 for Glioblastoma (October 31, 2018)
  • Optune for Glioblastoma (September 12, 2018)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Pfizer Could Launch US Bevacizumab This Year Despite Patent Thicket
  • Approval of SonoCloud-9 Ultrasound Device

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Fosun Gains Chinese Rights To MimiVax's SurVaxM
  • Deals Shaping The Medical Industry, October 2019
  • Tech Transfer Roundup: Mustang, Nationwide Children's Hospital Collaborate In Pediatric Glioblastoma
  • 1ST Bio, twoXAR Join Hands To Discover, Develop GBM Treatments
  • Troubled MabVax To Merge With Oncotelic
  • FUJIFILM Licenses Oncology Radiopharmaceutical To Novartis Affiliate

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of glioblastoma, 2017-26
  • Figure 2: Overview of pipeline drugs for glioblastoma in the US
  • Figure 3: Pipeline drugs for glioblastoma, by company
  • Figure 4: Pipeline drugs for glioblastoma, by drug type
  • Figure 5: Pipeline drugs for glioblastoma, by classification
  • Figure 6: Toca 511 for Glioblastoma (September 12, 2019): Phase III - Toca 5 (w/Lomustine)
  • Figure 7: Opdivo for Glioblastoma (September 5, 2019): Phase III - CheckMate-548
  • Figure 8: Opdivo for Glioblastoma (May 9, 2019): Phase III - CheckMate 498 (vs. Temozolomide)
  • Figure 9: MDNA55 for Glioblastoma (October 31, 2018): Phase IIb - MDNA55-05 (rGBM)
  • Figure 10: Key upcoming events in glioblastoma
  • Figure 11: Probability of success in the glioblastoma pipeline
  • Figure 12: Licensing and asset acquisition deals in glioblastoma, 2014-19
  • Figure 13: Parent patents in glioblastoma
  • Figure 14: Parent patents in glioblastoma [continued]
  • Figure 15: Clinical trials in glioblastoma
  • Figure 16: Top 10 drugs for clinical trials in glioblastoma
  • Figure 17: Top 10 companies for clinical trials in glioblastoma
  • Figure 18: Trial locations in glioblastoma
  • Figure 19: Glioblastoma trials status
  • Figure 20: Glioblastoma trials sponsors, by phase

LIST OF TABLES

  • Table 1: Global incident cases of glioblastoma, 2017-26
  • Table 2: Incident cases of glioblastoma, by gender, 2017
  • Table 3: Marketed drugs for glioblastoma
  • Table 4: Pipeline drugs for glioblastoma in the US
  • Table 5: Toca 511 for Glioblastoma (September 12, 2019)
  • Table 6: Opdivo for Glioblastoma (September 5, 2019)
  • Table 7: Mvasi for Glioblastoma (June 25, 2019)
  • Table 8: GammaTile for Glioblastoma (June 17, 2019)
  • Table 9: Ripretinib for Glioblastoma (June 11, 2019)
  • Table 10: AG-881 for Glioblastoma (June 3, 2019)
  • Table 11: Multiple Drugs for Glioblastoma (June 3, 2019)
  • Table 12: Opdivo for Glioblastoma (May 9, 2019)
  • Table 13: Optune for Glioblastoma (April 23, 2019)
  • Table 14: Optune for Glioblastoma (February 28, 2019)
  • Table 15: Voyager ulRFE System for Glioblastoma (December 14, 2018)
  • Table 16: SONOCLOUD for Glioblastoma (December 12, 2018)
  • Table 17: Optune for Glioblastoma (December 1, 2018)
  • Table 18: MDNA55 for Glioblastoma (October 31, 2018)
  • Table 19: Optune for Glioblastoma (September 12, 2018)
  • Table 20: Historical global sales, by drug ($m), 2014-18
  • Table 21: Forecasted global sales, by drug ($m), 2019-23
Back to Top